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Executive Summary
Problem
Many therapeutic proteins, including interferonbeta1b, a protein used in the treatment of
multiple sclerosis, create immune system responses in the patients, which is called
immunogenicity. The immune system attacks the protein and removes it from the body of the
patient, making the treatment much less effective and requiring large doses of protein to the
patient. Protein engineering and modifications can be utilized to reduce the immune response to
the protein, making protein therapy more effective. Zwitterions are especially promising due to
their highly hydrophilic nature and similarity to other naturally occurring proteins. This paper
investigates the addition of a string of 50 alternating lysine and glutamic acid residues (also
called KE50), which may eventually improve the performance of interferonbeta1b as a
therapeutic protein. The initial step to investigate the possibility of the KE50 modification is to
ensure that a protein with this modification will retain its function (the modification may
denature the protein and keep it from functioning correctly). To this end, the KE50 modification
was tested on a green fluorescent protein (AcGFP) which can be easily analyzed due to its
fluorescence which is only present when the protein is in its properly folded state.
Results
The KE50 modification was tested on a green fluorescent protein (AcGFP), and the fluorescence
of the modified protein (AcGFP KE50) was compared to the fluorescence of the original protein
(AcGFP). The original protein had a quantum yield of 0.80, an extinction coefficient of 32,200
1 1
M
cm
, and a brightness of 25,600. The modified protein had a quantum yield of 1.0, an

extinction coefficient of 16,600, and brightness of 16,600. The modified protein had 65% of the

brightness of the original protein. This demonstrates that the KE50 modification, while reducing
the function of the AcGFP, does not completely denature the protein. This is promising for future
work as the modification may be usable for medical proteins. Creating a KE50 modification for
interferonbeta1b was also attempted, but the protein was not successfully grown in an 
E.Coli
host within the allotted time.
Broader Implications
From a personal standpoint, completing this work allowed me to gain many skills and learn
about techniques used in genetic engineering and cell culture. Some of these techniques include
cell transformation, use of agar plates, batch cell culture, inducing protein expression, and
protein purification and analysis. I also gained more basic biology lab skills such as properly
using a pipettor, using an inoculation loop, and learning about sterilization procedures. This work
also allowed me to gain more skill in communication, working independently, and using
resources such as online protocols and previous research to create a research plan.
This work has broader applications to society in the medical applications. Therapeutic proteins
are used in the treatment of several diseases, and if the KE50 modification is effective for
AcGFP and interferonbeta1b, it may also be effective in improving the use of other therapeutic
proteins by reducing immunogenicity. More effective medical treatments are an important
societal benefit of biological research and genetic engineering. While other work is being
completed to improve immunogenicity of proteins, most of the methods involve processing the
natural protein in some way, while this method changes the protein itself without any additional
modification necessary after harvesting the protein.

Future Work
Future work in this area should include finding effective growth conditions for interferonbeta1b
in 
E.Coli 
(including selection of the plasmid and host cell strain), growing the natural and
modified forms of the protein, and testing the functionality of the modified and natural protein to
test if the modified protein can still be effective as a treatment. Next, the immunogenicity of the
modified protein should be tested and compared to the natural protein (this can be tested by
measuring the immune response (immunoglobulin production) of rat models upon injection with
the modified and natural protein).
For other students completing an Honors project, I would recommend starting early, making a
clear plan for the scope and schedule of the work, and to start writing the report as early as
possible. Other good advice for students completing an Honors project is to ask a lot of questions
and try to understand the purpose of all procedures before writing the report.

Introduction
Protein engineering has been an area of increasing research interest as the technology improves
and it is possible to create modified proteins which are more useful than their native forms.
Protein modifications have potential to improve protein characteristics such as thermostability,
pHinsensitivity, lower cell toxicity, and higher blood circulation times. This could extend to the
therapeutic use of proteins and create protein therapies which are more effective and less harmful
to the patient.
Green fluorescent protein (GFP) is a protein native to the jellyfish
Aequorea victoria
; GFP is
very useful in protein engineering studies due to its bright green color and fluorescence
properties which make the protein relatively easy to detect and quantify. The protein is
fluorescent in its properly folded state, and loses its fluorescence when denatured (Stepanenko et
al. 2013), which means that fluorescence of the protein can be used to measure to what extent the
bioactivity of GFP has been retained after modification. A variation of GFP, called AcGFP, was
used in this experiment: this mutant protein has a higher fluorescence than the natural strain.
Interferonβ1b (IFNβ1b) is a recombinant protein used in the treatment of multiple sclerosis.
Like many of the related interferon signaling proteins, IFNβ1b has a short residence time in the
body after treatment (known as serum halflife), which is partially due to immune response to the
protein. IFNβ1b is also hydrophobic, making the protein difficult to purify due to the
propensity to form aggregates (Basu et al, 2006).
The modification tested in this paper is the addition of a chain of 50 alternating lysine and
glutamic acid residues added near the Nterminus of the protein; this will be referred to as a
KE50 modification. The intended purpose of this modification is to improve blood circulation
time for medical proteins. The benefit of the KE50 modification comes from the zwitterionic
nature of the sequence; a zwitterion is a molecule that has both positive and negative charges,
and the KE50 modification alternates positively and negatively charged amino acids, creating a
zwitterionic molecule. Zwitterions can increase the aqueous solubility of large molecules, and
reduce immunogenicity of proteins. The overall goal of a KE50 modification is to create protein
molecules with higher stability and longer serum halflife which would make them more
effective for therapeutic use. Green fluorescent protein (AcGFP) and AcGFP KE50 (green
fluorescent protein with a KE50 modification) were created using a recombinant method with
E.Coli.
Background
Several methods have been attempted for the improvement of IFNβ1b and other proteins for
therapeutic use. A method used commercially for other proteins and attempted successfully for
IFNβ1b is the PEGylation method, which is the addition of polyethylene glycol polymer to the
protein. This modification was shown to decrease the immunogenicity of the protein, and
PEGylation is used in several commercial therapeutic proteins (Basu et al, 2006). Some issues
with this treatment method, including the formation of antiPEG antibodies upon repeated

exposure have raised concerns about the longterm viability of PEGylated proteins as a treatment
method (Zhang et. al. 2015).
A more recent method attempted for the modification of proteins for therapeutic use is the use of
zwitterions. Zwitterions have an advantage over PEGylation in that they more closely imitate
natural proteins (since natural proteins are zwitterionic) and they are more hydrophilic, which
might make them more effective in therapeutic applications. One method attempted using a
zwitterionic polycarboxybetaine (PCB) gel encapsulation on a protein uricase which increased
the circulation halflife of the polymer. Additionally, no evidence of immune reaction was found
in the rat model to either the protein or the polymer gel (Zhang et. al. 2015).
The KE50 modification attempted in this research has the some of the same advantages found in
the 2015 research by Zhang et al. by using zwitterions to increase hydrophilicity and protect the
protein from immune response. However, instead of encapsulating the nativetype protein in a
zwitterionic gel, a modification was made to the genetic information of the protein. Since many
therapeutic proteins are recombinant, genetic modification of the protein sequence can easily be
integrated into the largescale manufacturing process of the protein. This would allow the
creation of a zwitterionprotected protein without the additional processing step of zwitterionic
gel encapsulation. This method also has the advantage of being completely made of natural
protein and amino acids,which might avoid some of the immune reaction issues encountered
with the use of PEGylation.
Experimental Methods
Transformation of E.Coli cells with Recombinant DNA
The initial step in producing a sample protein in the lab is the transformation of 
Escherichia Coli
(E. Coli)
using a vector containing the desired protein DNA. The 

E.Coli
cells can be easily
grown in the lab setting, and will express the DNA of the protein coded for in the vector. The
first step, transformation, involves the uptake of the vector (in this case a recombinant plasmid
containing the protein of interest) into the 
E. Coli 
cells.
Competent 
E. Coli
cells were transformed with a recombinant plasmid pET28a (+) containing
the DNA sequence to code each desired protein. A standard transformation protocol was used.
After transformation, the cells were cultivated on an LB agar plate containing kanomycin
antibiotics. The native cell type does not have any resistance to kanomycin and should not be
able to grow; however, the cells that were successfully transformed with the plasmid will gain
resistance to the antibiotic and can grow colonies on the plate. This is how successfully
transformed cells are selected from the initial batch of competent cells. The successful colonies
can be grown in LB medium to increase the amount of transformed cells.

Protein Expression and Purification
After growing the required amount of transformed cells for protein synthesis, expression of the
protein in the plasmid is induced by adding 
Isopropyl βD1thiogalactopyranoside (IPTG).
IPTG induces transcription of DNA in the lac operon, which is the operon contained in the pET
28a(+) plasmid. IPTG was added to induce expression of the protein, and the cell culture was
allowed to ferment to express the protein.
After the protein expression was completed, the cells were centrifuged (to separate from the
growth medium) and lysed (to break the cells and release the protein into the lysis buffer).
Lysozyme, sonication, and nuclease were used to lyse the cells and break down the cell DNA to
allow separation of protein from other cell components. Centrifugation was used to separate the
protein (supernatant) from other cell components (precipitate).
The engineered recombinant proteins included a string of histidine residues near the Nterminus
of the protein, allowing for a simple separation of the target protein from other cell proteins. A
column with NiNTA HisTag resin was used, which has an affinity for the histidine tag on the
recombinant protein. When the protein sample is added to the column, the recombinant protein
will adsorb onto the resin in the column, allowing other proteins to flow through while retaining
the target protein. After several washing steps to remove other proteins, another buffer is used to
flood the column with a ion with high affinity for the resin (imidazole) to remove the target
protein from the column.
Confirming the Identity of Protein Samples
The presence of green fluorescence protein in a sample was confirmed using a microscope with a
colored light to view the fluorescence of the AcGFP inside of the cell samples.
To detect the presence of 
IFNβ1b, an SDSPAGE method was used to separate the proteins in a
sample by size. A standard protein ladder was used alongside unknown samples to estimate the
size of unknown proteins. To confirm the presence of IFNβ1b in a sample, a Western Blot
protocol was used. The primary antibody used in the Western Blot was IFN IgG interferonbeta
antibody, which will preferentially bind to IFNβ1b. The secondary antibody was Goat
antirabbit IgG, which binds to the primary antibody and allows detection using
spectrophotometric methods.
Fluorescence Measurements of AcGFP and AcGFPKE50
To determine the effect of the KE50 modification of protein folding and bioactivity, fluorescence
measurements were performed to compare AcGFP and AcGFPKE50. The measurements used
were quantum yield and extinction coefficient.
Quantum yield was measured by measuring the absorbance at 488 nm and the fluorescence
emission curves from 450750 nm. These measurements were made at 5 different concentrations
for the sample and for a reference of known quantum yield. In this experiment, the reference

used was fluorescein with a quantum yield of 0.92. The integral of the emission curve was
plotted against the absorbance for each concentration. This plot was approximately linear, and
the slope of the plot for the standard and sample was used in the following equation to calculate
the quantum yield:

ϕX = ϕST
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Where 
φ
is the quantum yield of the sample, φ
is the quantum yield of the standard, M
is the
X
ST
X
slope of the plot from the sample, M
is the slope of the plot from the standard, and η is the
ST
refractive index of the solvent (in this case η is the same for the standard and the sample).
The extinction coefficient was calculated using the measured absorbance for 5 different
concentrations of each protein, and using the BeerLambert law to plot the absorbance against
the concentration and pathlength in order to find the extinction coefficient (the slope of the
BeerLambert plot). The BeerLambert law is expressed with the following equation:

A = εCl
Where A is the absorbance, ε is the extinction coefficient, C is the concentration of the sample,
and l is the pathlength of the cuvette.

Data and Results

Figure 1. Integral of fluorescence emission curve from 480nm650nm versus the absorbance of
the sample at 488 nm at 5 different solution concentrations

Table 1. Slopes of plots from Figure 1 and quantum yield calculated for each sample using the
slope

Figure 2. Absorbance plotted against the concentration of the sample multiplied by the
pathlength: the slope of each linear plot is the extinction coefficient.

Table 2. Extinction coefficient found using Figure 2 and the brightness of each sample found by
multiplying the extinction coefficient times the quantum yield.

The modified protein had 65% of the brightness of the original protein.
Growth of IFNβ1b and IFNβ1b KE50 was attempted by using transformation in the same
manner as for AcGFP and AcGFP KE50. After separating the protein samples with SDSPAGE,
a Western blot procedure was used to detect the interferon protein. This was attempted with the
following 
E. Coli
strains and the transfection was not successful: Nova Blue, BL21, C41 (DE3)
and C43(DE3).
Discussion/Analysis
Transfection and growth of AcGFP and AcGFP KE50 proteins were successfully completed in
E. Coli
cells. The proteins were purified and tested to determine whether or not the protein would

successfully retain its function or if the KE50 modification would cause denaturation and loss of
function.
While the quantum yield of the AcGFP KE50 was higher than the original AcGFP, the extinction
coefficient of the AcGFP KE50 was lower, resulting in a lower overall brightness. The modified
protein had 65% of the brightness of the original protein. The quantum yield measures the
percentage of light absorbed that is emitted as fluorescence, and the extinction coefficient is a
measure of how much light is absorbed by a certain concentration of the substance. Therefore,
the brightness defined here as quantum yield multiplied by the extinction coefficient is a measure
of the fluorescence intensity per concentration.
The results show that the KE50 variant has lower brightness, meaning that the KE50
modification deforms the protein and reduces activity. However, the modification does not
completely eliminate the function of the protein, and may be an effective method to reduce
immunogenicity of therapeutic proteins. These results are consistent with current theories related
to sequencestructurefunction relationships. Altering the sequence of the protein affected the
structure of the protein, and therefore altered its function. While this paper demonstrates reduced
function of the protein, further work needs to be done to determine whether the KE50
modification has the intended effect of reduced immunogenicity.
The measured quantum yield and extinction coefficient for AcGFP was relatively close to the
1 1
literature value (φ = 0.82 and ε = 32,500 M
cmrespectively) (Clontech 2015). The measured
extinction coefficient may be less accurate due to uncertainty in the concentration measurement
method for the initial protein solution and uncertainty/inaccuracy of the dilutions. The quantum
yield measurement should be more accurate due to less reliance on the accuracy of the known
solution concentration. However, the quantum yield result for AcGFP KE50 of 1.0 is strange and
does not seem correct. Several of the data points used in the calculation of the quantum yield
seem to be outliers from the remaining data and may be inaccurate; further work will be
completed to determine the accuracy and repeatability of these results. One way to improve the
quantum yield measurement and ensure better results would be to use two fluorophore standards
instead of one and crossreference the results with known values to ensure that the equipment
and measurement methods are accurate.
The transformation of the 
E.Coli
strains with a pET28a(+) plasmid containing IFNβ1b and
IFNβ1b KE50 was not successful. The failure to produce detectable levels of IFNβ1b protein
could be due to several factors such as unsuccessful transformation, spontaneous genetic
mutation of the selected strains, protein toxicity to the cells, insolubility of the protein, or a
combination of factors. Since each separate attempt to transform, grow cells, express proteins,
and test for proteins takes several days, more time would be required to find a host cell strain and
plasmid combination that is able to express a significant amount of IFNβ1b protein using
E.Coli
cells.
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Appendices
Table A.1 Absorbance and integral of emission curve data used to calculate the quantum yield in
Figure 1

Table A.2. Raw data used to create Figure 2. Absorbance measured at 280 nm and molar
concentration of protein samples

Emission curve data of protein samples integrated to obtain value in Table A.1

Figure A.1. Emission curve of fluorescein sample 1

Figure A.2. Emission curve of fluorescein sample 2

Figure A.3. Emission curve of fluorescein sample 3

Figure A.4. Emission curve of fluorescein sample 4

Figure A.5. Emission curve of fluorescein sample 5

Figure A.6. Emission curve of AcGFP sample 1

Figure A.7. Emission curve of AcGFP sample 2

Figure A.8. Emission curve of AcGFP sample 3

Figure A.9. Emission curve of AcGFP sample 4

Figure A.10. Emission curve of AcGFP sample 5

Figure A.11. Emission curve of AcGFP KE50 sample 1

Figure A.12. Emission curve of AcGFP KE50 sample 2

Figure A.13. Emission curve of AcGFP KE50 sample 3

Figure A.14. Emission curve of AcGFP KE50 sample 4

Figure A.15. Emission curve of AcGFP KE50 sample 5

